• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿拉伯海湾合作委员会地区1型神经纤维瘤病的诊断与管理:挑战与建议

Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.

作者信息

Bashiri Fahad A, Hundallah Khaled, Abukhaled Musaad, Alyahya Mossaed Mohammed, Al Futaisi Amna, Alshowaeir Daniah, Al Tawari Asmaa, Abdullah Shaker, Maaz Ata Ur Rehman, AlShamsi Eman Taryam, Alshuaibi Walaa, Alotaibi Faisal, Aldhalaan Hesham

机构信息

Division of Pediatric Neurology, Department of Pediatrics, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

出版信息

Front Oncol. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176. eCollection 2024.

DOI:10.3389/fonc.2024.1323176
PMID:39257551
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11385870/
Abstract

Neurofibromatosis type 1 (NF1) is a complex multisystem genetic disorder that requires long-term, age-specific monitoring and multidisciplinary care. NF1 symptom burden can significantly affect the quality of life and impose a substantial economic burden on patients and their families. The approval and widespread availability of mitogen-activated protein kinase (MEK) inhibitors such as selumetinib for NF1-related plexiform neurofibromas have revolutionized the standard of care for patients with NF1, however their effective utilization hinges on early recognition of NF1. We present a consensus manuscript describing the challenges observed in the Arabian Gulf Cooperation Council (GCC) for diagnosing and managing NF1. Experts from the GCC also present recommendations for the early recognition and management of NF1 and its complications. A referral pathway that can play a crucial role in helping primary healthcare providers refer their patients to experts is also proposed. Increasing the availability and accessibility of genetic testing at an affordable cost and optimizing personalized NF1 care are essential for NF1 management. Developing regional guidelines for NF1 management and establishing NF1 centers of excellence may facilitate better care and outcomes for patients with NF1 in the GCC region.

摘要

1型神经纤维瘤病(NF1)是一种复杂的多系统遗传性疾病,需要进行长期、针对不同年龄段的监测和多学科护理。NF1的症状负担会显著影响生活质量,并给患者及其家庭带来沉重的经济负担。丝裂原活化蛋白激酶(MEK)抑制剂(如司美替尼)被批准用于治疗与NF1相关的丛状神经纤维瘤,且广泛可得,这彻底改变了NF1患者的护理标准,然而,它们的有效利用取决于对NF1的早期识别。我们发表了一篇共识文稿,描述了在阿拉伯海湾合作委员会(GCC)诊断和管理NF1过程中所观察到的挑战。GCC的专家们还提出了早期识别和管理NF1及其并发症的建议。还提出了一条转诊途径,它在帮助初级医疗保健提供者将患者转诊给专家方面可发挥关键作用。以可承受的成本提高基因检测的可及性和可用性,以及优化个性化的NF1护理,对于NF1的管理至关重要。制定NF1管理的区域指南并建立卓越的NF1中心,可能有助于为GCC地区的NF1患者提供更好的护理和治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/39a3bb970f19/fonc-14-1323176-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/dbd3c1ed5433/fonc-14-1323176-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1ee2a2c8b4ec/fonc-14-1323176-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1dadff581ab9/fonc-14-1323176-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/ae9420bf383d/fonc-14-1323176-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1ff14b84ae83/fonc-14-1323176-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/39a3bb970f19/fonc-14-1323176-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/dbd3c1ed5433/fonc-14-1323176-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1ee2a2c8b4ec/fonc-14-1323176-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1dadff581ab9/fonc-14-1323176-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/ae9420bf383d/fonc-14-1323176-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/1ff14b84ae83/fonc-14-1323176-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d521/11385870/39a3bb970f19/fonc-14-1323176-g006.jpg

相似文献

1
Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.阿拉伯海湾合作委员会地区1型神经纤维瘤病的诊断与管理:挑战与建议
Front Oncol. 2024 Aug 27;14:1323176. doi: 10.3389/fonc.2024.1323176. eCollection 2024.
2
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.MEK 抑制剂在 1 型神经纤维瘤病相关肿瘤中的应用及毒性管理。
Oncologist. 2020 Jul;25(7):e1109-e1116. doi: 10.1634/theoncologist.2020-0069. Epub 2020 Apr 22.
3
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.治疗决策和 MEK 抑制剂在 1 型神经纤维瘤病相关丛状神经纤维瘤患儿中的应用。
BMC Cancer. 2023 Jun 16;23(1):553. doi: 10.1186/s12885-023-10996-y.
4
Neurofibromatosis 1 (von Recklinghausen Disease).神经纤维瘤病1型(冯·雷克林豪森病)。
Keio J Med. 2025 Mar 25;74(1):37-41. doi: 10.2302/kjm.2023-0013-IR. Epub 2023 Aug 26.
5
Management of neurofibromatosis type 1-associated plexiform neurofibromas.1 型神经纤维瘤病相关丛状神经纤维瘤的治疗管理。
Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146.
6
Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.精准医学时代的神经纤维瘤病:MEK 抑制剂的发展和 Selumetinib 的最新成功
Curr Oncol Rep. 2021 Mar 15;23(4):45. doi: 10.1007/s11912-021-01032-y.
7
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.MEK 抑制剂治疗 1 型神经纤维瘤病表现:临床证据和共识。
Neuro Oncol. 2022 Nov 2;24(11):1845-1856. doi: 10.1093/neuonc/noac165.
8
A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.司美替尼治疗1型神经纤维瘤病相关丛状神经纤维瘤的综述
Ann Pharmacother. 2022 Jun;56(6):716-726. doi: 10.1177/10600280211046298. Epub 2021 Sep 18.
9
Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.关于1型神经纤维瘤病和丛状神经纤维瘤儿科患者中与司美替尼相关不良事件管理的共识建议。
Neurooncol Pract. 2024 Apr 27;11(5):515-531. doi: 10.1093/nop/npae038. eCollection 2024 Oct.
10
Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries' osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).海湾合作委员会(GCC)国家绝经后妇女骨质疏松症的诊断和管理:在欧洲临床和经济骨质疏松症和骨关节炎学会(ESCEO)的支持下,GCC 国家骨质疏松症学会的共识声明。
Arch Osteoporos. 2020 Jul 22;15(1):109. doi: 10.1007/s11657-020-00778-5.

引用本文的文献

1
[Application of multimodal intraoperative neurophysiological monitoring technology in neurofibromatosis type 1 related peripheral nerve tumor surgery].多模态术中神经生理监测技术在1型神经纤维瘤病相关周围神经肿瘤手术中的应用
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Oct 15;38(10):1202-1207. doi: 10.7507/1002-1892.202406065.

本文引用的文献

1
Epidemiology and Outcomes of Neurofibromatosis Type 1 (NF-1): Multicenter Tertiary Experience.1型神经纤维瘤病(NF-1)的流行病学与转归:多中心三级医疗机构经验
J Multidiscip Healthc. 2024 Mar 22;17:1303-1314. doi: 10.2147/JMDH.S454921. eCollection 2024.
2
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.治疗决策和 MEK 抑制剂在 1 型神经纤维瘤病相关丛状神经纤维瘤患儿中的应用。
BMC Cancer. 2023 Jun 16;23(1):553. doi: 10.1186/s12885-023-10996-y.
3
Phenotype and Genotype of Saudi Pediatric Patients With Neurofibromatosis Type 1: A Seven-Year Multicenter Experience From Saudi Arabia.
沙特阿拉伯1型神经纤维瘤病儿科患者的表型和基因型:沙特阿拉伯的七年多中心经验
Cureus. 2023 Apr 10;15(4):e37385. doi: 10.7759/cureus.37385. eCollection 2023 Apr.
4
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.在一项用于不可切除丛状神经纤维瘤的 1/2 期试验中,塞来替尼在儿童 1 型神经纤维瘤病中的长期安全性和疗效。
Neuro Oncol. 2023 Oct 3;25(10):1883-1894. doi: 10.1093/neuonc/noad086.
5
Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care.1型神经纤维瘤病(NF1):应对从儿科护理到成人护理的转变。
Pediatric Health Med Ther. 2023 Feb 9;14:19-32. doi: 10.2147/PHMT.S362679. eCollection 2023.
6
ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1.1型神经纤维瘤病患者的ERN GENTURIS肿瘤监测指南
EClinicalMedicine. 2023 Jan 13;56:101818. doi: 10.1016/j.eclinm.2022.101818. eCollection 2023 Feb.
7
Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent Gene Variants and Correlations with Neurocognitive Phenotype.神经纤维瘤病 1 型的基因型-表型相关性:新的和反复出现的基因突变的鉴定及其与神经认知表型的相关性。
Genes (Basel). 2022 Jun 23;13(7):1130. doi: 10.3390/genes13071130.
8
Neurological manifestations of neurofibromatosis type 1: our experience.神经纤维瘤病 1 型的神经学表现:我们的经验。
Neurologia (Engl Ed). 2022 Jun;37(5):325-333. doi: 10.1016/j.nrleng.2019.05.008. Epub 2021 May 26.
9
Management of neurofibromatosis type 1-associated plexiform neurofibromas.1 型神经纤维瘤病相关丛状神经纤维瘤的治疗管理。
Neuro Oncol. 2022 Nov 2;24(11):1827-1844. doi: 10.1093/neuonc/noac146.
10
Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1.1型神经纤维瘤病患者相关内分泌疾病的患病率
Avicenna J Med. 2022 Feb 18;12(1):16-20. doi: 10.1055/s-0041-1742197. eCollection 2022 Jan.